Good Review Management Guidance Splits Responsibility Between Sponsors & FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Final document decreases the draft's emphasis on pre-submission activities, noting that development is primarily sponsor's domain; submission shifts application management responsibility to FDA. Guidance outlines "model review management practices" and provides detailed links to relevant regulations.
You may also be interested in...
FDA’s Good Review Management Practices To Debut In “Near Future”
Even as the agency wrestles with the transformation brought by FDAAA, shifts in how it processes NDAs may be the "most important," CDER official says.
FDA’s Good Review Management Practices To Debut In “Near Future”
Even as the agency wrestles with the transformation brought by FDAAA, shifts in how it processes NDAs may be the "most important," CDER official says.
Most Recipients Of 74-Day Letters Believe They Facilitate Product Review – PhRMA Survey
Survey about 74-day letters and other good review management practices issues is previewed at DIA’s annual meeting in Atlanta..